We are now actively using the IBD Telemedicine Program. Established patients with an IBD specialist can request return telemedicine visits. This requires that you have a rapid internet connection, a computer with a webcam, and the ability to download software to your computer. The clerks will confirm these criteria when they check you out of clinic, and will schedule a telemedicine visit when you leave. You will receive a reminder for your visit, and will need to have your computer set up and your webcam ready to go 5 minutes before the visit time. You will be able to see your doctor, and your doctor will be able to see you, and discuss how you are doing and your ongoing care. You are still required to be seen in clinic once per year, and for urgent visits. Ask your doctor if an IBD telemedicine visit would be appropriate for your next follow up visit.

Save the Date!
Our annual Patient-2-Patient education Program brings both IBD patients, their families, and IBD physicians together. Join us on March 24th, 2018.
For more information contact: higginsSCteam@umich.edu
Currently Enrolling Clinical Trials

Ulcerative Colitis

**Hickory**—etrolizumab
*Subcutaneous Injection*
This is a phase three study for patients with moderate to severely active Ulcerative Colitis to evaluate the safety and effectiveness of etrolizumab, which targets anti-integrin b7.

**ABT494**—Upadacitinib
*Oral tablet*
This is a phase 2b/3 study for patients with moderate to severe Ulcerative Colitis to evaluate the safety and effectiveness of a new medication targeting JAK1.

**Upstart**—LY30937
*Oral tablet*
This is a phase 2 study to evaluate the safety and effectiveness while inducing remission in patients with moderate to severe Ulcerative Colitis over the course of 8 weeks.

**Legacy**
*Observational*
This is an observational study for patients who are taking Humira for up to 10 years. This is to observe the safety of long term use of Humira for patients who have Ulcerative Colitis.

**Bergamont**—etrolizumab
*Subcutaneous Injection*
This is a phase three study for patients with moderate to severely active Crohn’s disease to evaluate the safety and effectiveness of etrolizumab, which targets anti-integrin b7.

**PIONEER**
*Medical Food Supplement*
This study is to evaluate the effectiveness of an orally administered medical food in moderately to severely active subjects receiving induction therapy for Remicade or Humira.

**Dine CD**
*Dietary*
This study is to compare the effectiveness of a specific carbohydrate diet and Mediterranean style diet to induce symptoms and clinical remission in patients with active Crohn’s disease.

**APD371**—cannabinoid receptor agonist
*Oral tablet*
This is a phase 2a study to determine the tolerability and effectiveness of APD371 in patients who have mildly active Crohn’s disease with abdominal pain.

**Lilly**—LY3074828
*IV Induction / Subcutaneous injection for maintenance*
This is a phase two study for patients with moderate to severe Crohn’s disease to evaluate the safety and effectiveness of a new medication targeting interleukin-23.

Coming Soon:
**ABT494**—Upadacitinib
This is a study for patients with moderate to severe Crohns disease.

**ABBV-066**—Risankizumab
This is a study for patients with moderate to severe Crohns disease.

WE NEED YOU!
In addition to the clinical trials we have available, there are many other kinds of research going on within our group. We are always looking for volunteers who are willing to provide samples (i.e. stool, blood, biopsies from colonoscopies). Sometimes, we may just need someone willing to fill out a survey every few months. Whatever your comfort level, we likely have a study that would suit you.

Your non-IBD friends and family don’t have to feel left out either. There are plenty of opportunities for healthy controls to contribute to our research. Contact us at higginsSCteam@umich.edu.